title: EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia.
authors.forename: T
authors.initials: T
authors.lastname: Leguay
authors.forename: C
authors.initials: C
authors.lastname: Foucaud
authors.forename: M
authors.initials: M
authors.lastname: Parrens
authors.forename: O
authors.initials: O
authors.lastname: Fitoussi
authors.forename: K
authors.initials: K
authors.lastname: Bouabdallah
authors.forename: M A
authors.initials: MA
authors.lastname: Belaud-Rotureau
authors.forename: R
authors.initials: R
authors.lastname: Tabrizi
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: A
authors.initials: A
authors.lastname: Pigneux
authors.forename: N
authors.initials: N
authors.lastname: Milpied
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D001549:Benzamides; D049109:Cell Proliferation; D005260:Female; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007679:Kidney Medulla / Q000821:virology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008099:Liver / Q000821:virology*; D008232:Lymphoproliferative Disorders / Q000139:chemically induced / Q000378:metabolism / Q000821:virology*; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012008:Recurrence; D013154:Spleen / Q000821:virology*; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate